LEADER 03079nam 22006255 450 001 9910921013803321 005 20250107115228.0 010 $a9783031679070 010 $a3031679075 024 7 $a10.1007/978-3-031-67907-0 035 $a(CKB)37155971400041 035 $a(MiAaPQ)EBC31875770 035 $a(Au-PeEL)EBL31875770 035 $a(DE-He213)978-3-031-67907-0 035 $a(OCoLC)1483253183 035 $a(EXLCZ)9937155971400041 100 $a20250107d2024 u| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aStrong Light?Matter Interactions in Extreme Plasmonic and Mie-Resonant Systems /$fby P. Elli Stamatopoulou 205 $a1st ed. 2024. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2024. 215 $a1 online resource (0 pages) 225 1 $aSpringer Theses, Recognizing Outstanding Ph.D. Research,$x2190-5061 311 08$a9783031679063 311 08$a3031679067 327 $aIntroduction -- Theory -- Strong Coupling in Photonics -- Weak Coupling of Nanoparticles with Quantum Emitters -- Interaction of Nanoparticles with Electron Beams -- Summary and Conclusions. 330 $aCollective excitations in matter, either in the form of plasmons in metals or Mie resonances in high-index dielectrics, constitute fundamental building blocks for photonic applications, including optical and quantum communications, biosensing, and polaritonic chemistry. Motivated by these prospects, this book explores excitations sustained in metallic and dielectric nanocavities and their interaction with light, quantum emitters, and swift electrons. The book presents analytic methods for describing the strong and weak coupling between spherical nanocavities and optical transitions in matter, while also analyzing the impact of nonlocality on the coupling, when considering extremely small metallic structures. Besides light-based spectroscopy, it examines electrons as sources for probing optical excitations in matter and provides analytic tools for simulating measurements in cathodoluminescence and electron energy-loss spectroscopy. 410 0$aSpringer Theses, Recognizing Outstanding Ph.D. Research,$x2190-5061 606 $aOptics 606 $aNanophotonics 606 $aPlasmonics 606 $aCondensed matter 606 $aOptics and Photonics 606 $aNanophotonics and Plasmonics 606 $aStrongly Correlated Systems 615 0$aOptics. 615 0$aNanophotonics. 615 0$aPlasmonics. 615 0$aCondensed matter. 615 14$aOptics and Photonics. 615 24$aNanophotonics and Plasmonics. 615 24$aStrongly Correlated Systems. 676 $a535 700 $aStamatopoulou$b P. Elli$01782311 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910921013803321 996 $aStrong Light?Matter Interactions in Extreme Plasmonic and Mie-Resonant Systems$94370289 997 $aUNINA LEADER 05409nam 2201405z- 450 001 9910743279303321 005 20230911 035 $a(CKB)5690000000228514 035 $a(oapen)doab113918 035 $a(EXLCZ)995690000000228514 100 $a20230920c2023uuuu -u- - 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aIntegrating Clinical and Translational Research Networks-Building Team Medicine - Series 2 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2023 215 $a1 online resource (230 p.) 311 08$a3-0365-8473-0 330 $aThe previous Special Issue of the Journal of Clinical Medicine, 'Integrating Clinical and Translational Research Networks-Building Team Medicine', which highlighted our collective experience from the City of Hope and was published in 2020, was a huge success. Buoyed by the enthusiastic response from our peers and colleagues, we have embarked on bringing out Volume 2. The basic theme is the same-namely, integrating academic medical centers with the clinical network in various geographic locations to ensure that all patients, regardless of their physical proximity to major medical institutions, can benefit from recent clinical advances. As in the previous volume on the importance of including basic research scientists, our aim here is to highlight translational research approaches that leverage the combined knowledge, skills, experience, expertise, and vision of clinicians in academic medical centers, their affiliated community centers, and hospitals, together with those of basic research scientists. However, here we also strive to include bioinformaticians and data scientists. We look forward to sharing our team medicine experience with our colleagues around the world and trust that they will find the approach described in the articles included in this Special issue useful for guiding their approaches for treating cancer patients. 606 $aMedicine and Nursing$2bicssc 606 $aOncology$2bicssc 610 $aadaptive therapy 610 $aadvanced soft tissue sarcoma 610 $aartificial intelligence 610 $aATM mutation 610 $abrain metastases 610 $aBRIP1 mutation 610 $acancer disparities 610 $acancer prevention 610 $acancer systems biology 610 $acare satisfaction 610 $acisplatin 610 $aCity of Hope 610 $aclinical care network 610 $aclinical network systems biology 610 $aclinical trials 610 $acollaboration 610 $acolorectal cancer survivor 610 $acombinational therapy 610 $acommunity clinical network 610 $acommunity practice 610 $acomplex case discussions 610 $acontinuous therapy 610 $acutaneous cancers 610 $adecision support 610 $adelivery of health care 610 $adrug resistance 610 $adrug tolerance 610 $aeco-evolutionary 610 $aEGFR 610 $aemergency utilization 610 $aendometrial cancer 610 $aepigenetics 610 $agenetic/nongenetic 610 $agenomic-driven 610 $agroup behavior 610 $agut microbiome 610 $aIDPs 610 $aimaging 610 $aimmune checkpoint inhibitors 610 $aimmunotherapy 610 $aimplementation 610 $aimplementation science 610 $aintegration 610 $aintegrative oncology 610 $aintermittent therapy 610 $aintrinsically disordered proteins 610 $aLDCT 610 $aleptomeningeal metastases 610 $alow dose Ct scans 610 $alung cancer screening 610 $amathematical modeling 610 $amelanoma 610 $ametastasis-directed therapy 610 $aMidwest Sarcoma Trials Partnership 610 $aminority health 610 $amultidisciplinary tumor board 610 $an/a 610 $aNET VITALS 610 $aneuroendocrine tumors 610 $anon-small cell lung cancer 610 $aOlaparib 610 $aoligometastatic 610 $aoncology 610 $aoncology pathways 610 $aoncolytic virotherapy 610 $apandemic 610 $aPARP inhibition 610 $apathologic complete response 610 $apathways to success 610 $apersonalized medicine 610 $aphase 1 610 $aphenotype switching 610 $aPOLE mutation 610 $aprecision medicine 610 $aprostate cancer 610 $aPSMA PET 610 $aRAD51C mutation 610 $arenal cell carcinoma 610 $asarcoma treatment 610 $aSARS-CoV-2 610 $aself-assessment 610 $asmoking cessation 610 $asubspecialty expertise 610 $aT-VEC 610 $atargeted therapy 610 $ateam medicine 610 $aTeam Medicine 610 $aTMB high 610 $atobacco control 610 $atranslational research 610 $atumor board 615 7$aMedicine and Nursing 615 7$aOncology 906 $aBOOK 912 $a9910743279303321 996 $aIntegrating Clinical and Translational Research Networks-Building Team Medicine - Series 2$94417399 997 $aUNINA